{"id":39928,"date":"2025-08-22T15:00:25","date_gmt":"2025-08-22T07:00:25","guid":{"rendered":"https:\/\/flcube.com\/?p=39928"},"modified":"2025-08-22T15:00:26","modified_gmt":"2025-08-22T07:00:26","slug":"tianjin-lisheng-plans-rmb-1-billion-fund-with-strategic-partners","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39928","title":{"rendered":"Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners"},"content":{"rendered":"\n<p>Tianjin Lisheng Pharmaceutical Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/002393:SHE\">SHE: 002393<\/a>), based in China, announced plans to co-establish the Jiansheng Guoxin Taida Equity Investment Fund Partnership with a group of partners, including CCB Equity Investment Management Co., Ltd., Tianjin Teda Private Equity Fund Management Co., Ltd., and others. The fund will have a total scale of RMB 1 billion, with an initial contribution of RMB 500 million. Lisheng Pharmaceutical will subscribe to 34.75% of the fund.<\/p>\n\n\n\n<p><strong>Fund Details<\/strong><br>The Jiansheng Guoxin Taida Equity Investment Fund Partnership aims to invest in strategic emerging industries. The fund&#8217;s establishment is subject to final registration with the market supervision and administration authority.<\/p>\n\n\n\n<p><strong>Partners Involved<\/strong><br>Key partners include CCB Equity Investment Management Co., Ltd., Tianjin Teda Private Equity Fund Management Co., Ltd., Gongqingcheng Jianxing Investment Partnership, Tianjin Teda International Holdings (Group) Co., Ltd., Tianjin Guoxin No.1 Industrial Development Master Fund Partnership, and CCB Leading Strategic Emerging Industries Development Fund.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u529b\u751f\u5236\u836f\uff1a\u5173\u4e8e\u516c\u53f8\u53c2\u4e0e\u8bbe\u7acb\u4ea7\u4e1a\u533b\u836f\u57fa\u91d1\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u529b\u751f\u5236\u836f\uff1a\u5173\u4e8e\u516c\u53f8\u53c2\u4e0e\u8bbe\u7acb\u4ea7\u4e1a\u533b\u836f\u57fa\u91d1\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-5afdb3b3-b46e-46f7-bea9-0dad57d16fa4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u529b\u751f\u5236\u836f\uff1a\u5173\u4e8e\u516c\u53f8\u53c2\u4e0e\u8bbe\u7acb\u4ea7\u4e1a\u533b\u836f\u57fa\u91d1\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a.pdf\">\u529b\u751f\u5236\u836f\uff1a\u5173\u4e8e\u516c\u53f8\u53c2\u4e0e\u8bbe\u7acb\u4ea7\u4e1a\u533b\u836f\u57fa\u91d1\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u529b\u751f\u5236\u836f\uff1a\u5173\u4e8e\u516c\u53f8\u53c2\u4e0e\u8bbe\u7acb\u4ea7\u4e1a\u533b\u836f\u57fa\u91d1\u66a8\u5173\u8054\u4ea4\u6613\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5afdb3b3-b46e-46f7-bea9-0dad57d16fa4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), based in China, announced plans to co-establish the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":39932,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,806,1544],"class_list":["post-39928","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-lisheng-pharmaceutical","tag-she-002393"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), based in China, announced plans to co-establish the Jiansheng Guoxin Taida Equity Investment Fund Partnership with a group of partners, including CCB Equity Investment Management Co., Ltd., Tianjin Teda Private Equity Fund Management Co., Ltd., and others. The fund will have a total scale of RMB 1 billion, with an initial contribution of RMB 500 million. Lisheng Pharmaceutical will subscribe to 34.75% of the fund.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39928\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners\" \/>\n<meta property=\"og:description\" content=\"Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), based in China, announced plans to co-establish the Jiansheng Guoxin Taida Equity Investment Fund Partnership with a group of partners, including CCB Equity Investment Management Co., Ltd., Tianjin Teda Private Equity Fund Management Co., Ltd., and others. The fund will have a total scale of RMB 1 billion, with an initial contribution of RMB 500 million. Lisheng Pharmaceutical will subscribe to 34.75% of the fund.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39928\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-22T07:00:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-22T07:00:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2209.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39928#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39928\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners\",\"datePublished\":\"2025-08-22T07:00:25+00:00\",\"dateModified\":\"2025-08-22T07:00:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39928\"},\"wordCount\":161,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39928#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2209.webp\",\"keywords\":[\"Finance\",\"Lisheng Pharmaceutical\",\"SHE: 002393\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39928#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39928\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39928\",\"name\":\"Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39928#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39928#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2209.webp\",\"datePublished\":\"2025-08-22T07:00:25+00:00\",\"dateModified\":\"2025-08-22T07:00:26+00:00\",\"description\":\"Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), based in China, announced plans to co-establish the Jiansheng Guoxin Taida Equity Investment Fund Partnership with a group of partners, including CCB Equity Investment Management Co., Ltd., Tianjin Teda Private Equity Fund Management Co., Ltd., and others. The fund will have a total scale of RMB 1 billion, with an initial contribution of RMB 500 million. Lisheng Pharmaceutical will subscribe to 34.75% of the fund.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39928#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39928\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39928#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2209.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2209.webp\",\"width\":1080,\"height\":608,\"caption\":\"Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39928#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners - Insight, China&#039;s Pharmaceutical Industry","description":"Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), based in China, announced plans to co-establish the Jiansheng Guoxin Taida Equity Investment Fund Partnership with a group of partners, including CCB Equity Investment Management Co., Ltd., Tianjin Teda Private Equity Fund Management Co., Ltd., and others. The fund will have a total scale of RMB 1 billion, with an initial contribution of RMB 500 million. Lisheng Pharmaceutical will subscribe to 34.75% of the fund.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39928","og_locale":"en_US","og_type":"article","og_title":"Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners","og_description":"Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), based in China, announced plans to co-establish the Jiansheng Guoxin Taida Equity Investment Fund Partnership with a group of partners, including CCB Equity Investment Management Co., Ltd., Tianjin Teda Private Equity Fund Management Co., Ltd., and others. The fund will have a total scale of RMB 1 billion, with an initial contribution of RMB 500 million. Lisheng Pharmaceutical will subscribe to 34.75% of the fund.","og_url":"https:\/\/flcube.com\/?p=39928","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-22T07:00:25+00:00","article_modified_time":"2025-08-22T07:00:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2209.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39928#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39928"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners","datePublished":"2025-08-22T07:00:25+00:00","dateModified":"2025-08-22T07:00:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39928"},"wordCount":161,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39928#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2209.webp","keywords":["Finance","Lisheng Pharmaceutical","SHE: 002393"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39928#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39928","url":"https:\/\/flcube.com\/?p=39928","name":"Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39928#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39928#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2209.webp","datePublished":"2025-08-22T07:00:25+00:00","dateModified":"2025-08-22T07:00:26+00:00","description":"Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), based in China, announced plans to co-establish the Jiansheng Guoxin Taida Equity Investment Fund Partnership with a group of partners, including CCB Equity Investment Management Co., Ltd., Tianjin Teda Private Equity Fund Management Co., Ltd., and others. The fund will have a total scale of RMB 1 billion, with an initial contribution of RMB 500 million. Lisheng Pharmaceutical will subscribe to 34.75% of the fund.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39928#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39928"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39928#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2209.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2209.webp","width":1080,"height":608,"caption":"Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39928#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2209.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39928"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39928\/revisions"}],"predecessor-version":[{"id":39933,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39928\/revisions\/39933"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39932"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}